296 related articles for article (PubMed ID: 36479122)
1. Molecular subtypes and a prognostic model for hepatocellular carcinoma based on immune- and immunogenic cell death-related lncRNAs.
He M; Gu W; Gao Y; Liu Y; Liu J; Li Z
Front Immunol; 2022; 13():1043827. PubMed ID: 36479122
[TBL] [Abstract][Full Text] [Related]
2. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma.
Xu G; Jiang Y; Li Y; Ge J; Xu X; Chen D; Wu J
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16261-16277. PubMed ID: 37698679
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value and immune landscapes of immunogenic cell death-related lncRNAs in hepatocellular carcinoma.
Chen W; Shu K; Cai C; Ding J; Zhang X; Zhang W; Wang K
Biosci Rep; 2023 Sep; 43(9):. PubMed ID: 37584192
[TBL] [Abstract][Full Text] [Related]
4. A novel prognostic signature based on immunogenic cell death score predicts outcomes and response to transcatheter arterial chemoembolization and immunotherapy in hepatocellular carcinoma.
Zhang Y; Yang J; Xie S; Chen H; Zhong J; Lin X; Yu Z; Xia J
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11411-11429. PubMed ID: 37382674
[TBL] [Abstract][Full Text] [Related]
5. A novel prognostic model based on immunogenic cell death-related genes for improved risk stratification in hepatocellular carcinoma patients.
Liu T; Chen X; Peng B; Liang C; Zhang H; Wang S
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10255-10267. PubMed ID: 37269346
[TBL] [Abstract][Full Text] [Related]
6. Identification of a DNA damage repair-related LncRNA signature for predicting the prognosis and immunotherapy response of hepatocellular carcinoma.
Huang F; Zhang C; Yang W; Zhou Y; Yang Y; Yang X; Guo W; Wang B
BMC Genomics; 2024 Feb; 25(1):155. PubMed ID: 38326754
[TBL] [Abstract][Full Text] [Related]
7. Identification of a CD4+ conventional T cells-related lncRNAs signature associated with hepatocellular carcinoma prognosis, therapy, and tumor microenvironment.
Zhu L; Zhang XP; Xu S; Hu MG; Zhao ZM; Zhao GD; Xiao ZH; Liu R
Front Immunol; 2022; 13():1111246. PubMed ID: 36700197
[TBL] [Abstract][Full Text] [Related]
8. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
9. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.
Zhao QJ; Zhang J; Xu L; Liu FF
World J Gastroenterol; 2018 Aug; 24(30):3426-3439. PubMed ID: 30122881
[TBL] [Abstract][Full Text] [Related]
10. Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma.
Li R; Jin C; Zhao W; Liang R; Xiong H
BMC Gastroenterol; 2022 Nov; 22(1):450. PubMed ID: 36344926
[TBL] [Abstract][Full Text] [Related]
11. A Novel Cholesterol Metabolism-Related lncRNA Signature Predicts the Prognosis of Patients with Hepatocellular Carcinoma and Their Response to Immunotherapy.
Lei H; Xiang T; Zhu H; Hu X
Front Biosci (Landmark Ed); 2024 Mar; 29(3):129. PubMed ID: 38538256
[TBL] [Abstract][Full Text] [Related]
12. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
14. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma.
Xu Q; Wang Y; Huang W
Int Immunopharmacol; 2021 Mar; 92():107333. PubMed ID: 33486322
[TBL] [Abstract][Full Text] [Related]
15. Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma.
Xu Z; Peng B; Liang Q; Chen X; Cai Y; Zeng S; Gao K; Wang X; Yi Q; Gong Z; Yan Y
Front Immunol; 2021; 12():719175. PubMed ID: 34603293
[TBL] [Abstract][Full Text] [Related]
16. Identification and validation of a fatty acid metabolism-related lncRNA signature as a predictor for prognosis and immunotherapy in patients with liver cancer.
Chen E; Yi J; Jiang J; Zou Z; Mo Y; Ren Q; Lin Z; Lu Y; Zhang J; Liu J
BMC Cancer; 2022 Oct; 22(1):1037. PubMed ID: 36195833
[TBL] [Abstract][Full Text] [Related]
17. Immunogenic landscape and risk score prediction based on unfolded protein response (UPR)-related molecular subtypes in hepatocellular carcinoma.
Guo H; Zhang S; Zhang B; Shang Y; Liu X; Wang M; Wang H; Fan Y; Tan K
Front Immunol; 2023; 14():1202324. PubMed ID: 37457742
[TBL] [Abstract][Full Text] [Related]
18. Investigation of Hippo pathway-related prognostic lncRNAs and molecular subtypes in liver hepatocellular carcinoma.
Su Q; Hua F; Xiao W; Liu B; Wang D; Qin X
Sci Rep; 2023 Mar; 13(1):4521. PubMed ID: 36941336
[TBL] [Abstract][Full Text] [Related]
19. Immune-related long noncoding RNA signature for predicting survival and immune checkpoint blockade in hepatocellular carcinoma.
Zhang Y; Zhang L; Xu Y; Wu X; Zhou Y; Mo J
J Cell Physiol; 2020 Dec; 235(12):9304-9316. PubMed ID: 32330311
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA-based signature for predicting prognosis of hepatocellular carcinoma.
Cao J; Wu L; Lei X; Shi K; Shi L; Shi Y
Bioengineered; 2021 Dec; 12(1):673-681. PubMed ID: 33622186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]